Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Has announcements × larotrectinib × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 3 selpercatinib 2 obinutuzumab 2 ibrutinib 2 Rituximab 2 Nivolumab 2 Midazolam 2 Ipilimumab 2 Crizotinib 2 zanubrutinib 1 venetoclax 1 toripalimab 1 tocilizumab 1 tazemetostat 1 tagraxofusp 1 sotorasib 1 sacituzumab govitecan 1 romiplostim 1 revumenib 1 repotrectinib 1 prednisolone phosphate 1 prednisolone acetate 1 pralsetinib 1 polatuzumab vedotin 1 pirtobrutinib 1 naxitamab 1 mobocertinib 1 lorlatinib 1 lenvatinib 1 larotrectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02637687 2025-06-22

SCOUT

Bayer

Phase 1/2 Active not recruiting

154 enrolled 3 FDA

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡